Details of the Drug Formulations

General Information of Drug (ID: DM9CIUW)

• Drug Name: Ribociclib Succinate Drug Info
• Synonyms: 1374639-75-4; LEE011 succinate; LEE011 (succinate); UNII-BG7HLX2919; LEE011-BBA; Ribociclib succinate [USAN]; BG7HLX2919; Kisqali (TN); Ribociclib succinate (USAN); LEE-011 succinate; SCHEMBL2684999; EX-A1586; HY-15777B; 1374639-75-4 (succinate); AKOS030526460; CS-2277; ACN-040739

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[1]
Hormone receptor positive and HER2-negative advanced or metastatic breast cancer	2C60-2C65	Approved	[2]

• Cross-matching ID:
  PubChem CID: 57334219
  CAS Number: 1374639-75-4
  TTD ID: D01HVT
  INTEDE ID: DR1415
  ACDINA ID: D01386

Full List of Drug Formulations Containing This Drug

Ribociclib Succinate 200mg tablet

Company	Formulation ID	FDA Description
Novartis	F23272	Colloidal Silicon Dioxide; Crospovidone; Hydroxypropylcellulose; Magnesium Stearate; Microcrystalline Cellulose; Iron Oxide Black; Iron Oxide Red; Lecithin (Soya); Polyvinyl Alcohol (Partially Hydrolysed); Talc; Titanium Dioxide; Xanthan Gum

References

• [1] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018